Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8506 to 8520 of 8990 results

  1. Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]

    Discontinued Reference number: GID-TA10334

    Technology appraisal guidance
    Discontinued

  2. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]

    In development Reference number: GID-TA11640 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over [TSID12091]

    In development Reference number: GID-TA11679 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Pralsetinib for thyroid cancer [ID4018]

    Discontinued Reference number: GID-TA10910

    Technology appraisal guidance
    Discontinued

  5. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    Discontinued Reference number: GID-TA11033

    Technology appraisal guidance
    Discontinued

  6. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    In development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Digital technologies for multidisciplinary weight management

    In development Reference number: GID-HTE10077 Expected publication date: TBC

    Health technology evaluations
    In development

  8. Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]

    In development Reference number: GID-TA11750 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]

    In development Reference number: GID-TA11664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Venglustat for treating gangliosidoses in people 2 years and over [ID6358]

    Discontinued Reference number: GID-TA11396

    Technology appraisal guidance
    Discontinued

  11. Pegvaliase for treating phenylketonuria [ID1110]

    Discontinued Reference number: GID-TA10345

    Technology appraisal guidance
    Discontinued

  12. Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]

    Discontinued Reference number: GID-TA10663

    Technology appraisal guidance
    Discontinued

  13. Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223

    Discontinued Reference number: GID-HST10019

    Highly specialised technologies guidance
    Discontinued

  14. Type 2 diabetes in adults: management - insulin therapy

    Discontinued Reference number: GID-NG10375

    NICE guideline
    Discontinued

  15. Haemochromatosis

    Discontinued Reference number: GID-NG10287

    NICE guideline
    Discontinued